Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer

Fig. 2

MEDI3039-dependent cell death is mediated by DR5. a MB231 cells were transfected with Neg Ctl. siRNA (siNeg), two separate DR4 siRNAs (siDR4 #1 and #3), or two separate DR5 siRNAs (siDR5 #1 and #6). Two days later, MEDI3039 was added and incubated for an additional 3 days. Cell viability was examined by MTS assays. Data is shown as average ± SEM of three independent experiments. ****p < 0.0001, two-way ANOVA, siNeg vs siDR5_#1, siNeg vs siDR5_#6. b The effect of MEDI3039 at 1 pM was compared among siNeg, siDR4, and siDR5. Statistical analysis was performed with Student’s t test. c Representative western blot showing effective knockdown of endogenous DR4 and DR5 proteins by corresponding siRNAs. HSC70 was used as a loading control. d Quantitative analysis of band intensities in western blot analyses. Data is shown as mean ± SEM of three independent experiments, and band intensities are shown as % relative to siNeg ctl

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us